ADS-ADEA 2016* , ,
Presentations this author is a contributor to:
Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled trial (#178)
11:30 AM
John Prins
ADS Clinical Orals - Obesity & Diabetes
Early weight loss responders to liraglutide 3.0 mg had greater weight loss, regression to normoglycaemia, and reduced T2D development at 3 years vs early non-responders: SCALE Obesity and Prediabetes (#245)
2:00 PM
Samantha Hocking
ADS Clinical Poster Session - Prevention of type 2 diabetes
Characteristics of individuals developing type 2 diabetes in the SCALE Obesity and Prediabetes randomised, double-blind, liraglutide vs placebo trial (#246)
2:00 PM
Samantha Hocking
ADS Clinical Poster Session - Prevention of type 2 diabetes